ZYKADIA
PeakNDAORALCAPSULEPriority Review
Approved
Apr 2014
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
3/8 — Basic
Priority Review
ZYKADIA by Novartis is inhibitor. First approved in 2014.
Drug data last refreshed 13h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZYKADIA is an oral small-molecule kinase inhibitor approved by the FDA in April 2014 as an NDA from Novartis. The drug's specific mechanism of action and indications are not disclosed in available data, but it is formulated as a capsule for oral administration. It currently occupies peak lifecycle status within its market.
Peak5.4 years to LOE
At peak lifecycle stage, ZYKADIA likely supports a mature commercial organization with established field force, patient support programs, and payer management teams managing market share against competitors.
Mechanism of Action
inhibitor. Targets of ceritinib inhibition identified in either biochemical or cellular assays at clinically relevant concentrations include ALK, insulin-like growth factor 1 receptor (IGF-1R), insulin receptor (InsR), and ROS1. Among these, ceritinib is most active against ALK. Ceritinib inhibited…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ZYKADIA currently shows zero linked job openings, reflecting the mature, stable state of a peak-lifecycle product with an established commercial infrastructure. Career opportunities are concentrated in brand management, sales optimization, payer negotiation, and patient support rather than new product launch or clinical development roles.
Worked on ZYKADIA at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.